Preclinical CRO Global Market Report 2024

The preclinical cro market has grown strongly in recent years. It will grow from $5.15 billion in 2023 to $5.66 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth observed in the historical period can be attributed to various factors, including a rising demand for accelerated drug development, the adoption of cost containment strategies, a strategic focus on core competencies, adherence to regulatory compliance requirements, and the globalization of clinical trials.

The preclinical cro market is expected to see strong growth in the next few years. It will grow to $7.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The projected growth in the forecast period is associated with several factors, particularly the rising significance of personalized medicine, an increased focus on addressing rare diseases and orphan drugs, a surge in outsourcing within the biopharmaceutical sector, a dedicated emphasis on biomarker research, and a growing demand for the generation of real-world evidence. Key trends expected to shape this period include the integration of artificial intelligence (AI), the proliferation of oncology research, advancements in omics technologies, progress in advanced in vitro and in vivo models, and collaborative efforts in translational research.

The increasing demand for preclinical trials is expected to drive the expansion of the preclinical Contract Research Organization (CRO) market in the near future. Preclinical trials involve studies conducted on medicinal treatments or therapies before human volunteers become test subjects. These studies, which include innovative medical devices, prescription medications, and diagnostics, aim to establish a safe initial dosage for first-in-human research and evaluate potential product toxicity. The significance of preclinical trials in drug development is growing, propelled by a heightened focus on the safety and efficacy of emerging drugs. As of April 2023, the National Library of Medicine reported 399,501 preclinical studies conducted by the end of 2021 and 437,536 preclinical trials completed by the end of 2022, highlighting the escalating demand for preclinical trials and its consequential impact on the preclinical CRO market.

The increasing need for outsourcing services is poised to be a driving force behind the growth of the preclinical CRO market in the coming years. Outsourcing services involve contracting with third-party vendors to manage specific business tasks or operations. The complexity of preclinical research is on the rise, requiring specialized skills and expertise not always available in-house for pharmaceutical and biotechnology companies. Outsourcing to preclinical CROs allows companies to access the necessary expertise without the burden of building internal capabilities, enabling them to focus on core business activities while ensuring the completion of preclinical research. In April 2023, a survey by BioPlan Associates Inc. revealed that 84.6% of biomanufacturers are outsourcing analytical testing, and 74.5% are outsourcing toxicity testing in 2023. This underscores the increasing reliance on outsourcing services, contributing to the upward trajectory of the preclinical CRO market.

Technological advancements are a prominent trend gaining momentum in the preclinical Contract Research Organization (CRO) market, with significant companies in the sector adopting innovative technologies to strengthen their market positions. In February 2023, BenchSci, a Canada-based AI solutions company specializing in preclinical Research and Development (R&D), introduced ASCEND, an end-to-end Software as a Service (SaaS) platform for preclinical drug discovery. Leveraging artificial intelligence, ASCEND accelerates the preclinical phase of drug development pipelines by deriving biological insights into the foundational aspects of diseases. BenchSci's machine learning technology is employed to extract experimental data from both internal and external sources, enabling a comparison of results using curated ontology datasets. This approach facilitates the creation of evidence-based maps illustrating the biological processes underlying various diseases.

Key players in the preclinical CRO landscape are actively engaging in collaborations and partnerships to enhance their service offerings. Strategic partnerships, characterized by structured affiliations through business agreements or contracts, are a focal point in this context. In February 2022, IonsGate Preclinical Services Inc., a Canada-based CRO specializing in preclinical research services, announced a partnership with Insilicotrials Technologies Srl, an Italy-based provider of specialized consultancy for clinical trial solutions. This collaborative effort aims to leverage innovative technologies to expedite drug discovery processes, enabling more comprehensive preclinical testing capable of identifying potential safety risks at earlier stages of development.

In June 2022, Asahi Kasei Medical Co. Ltd., a Japan-based chemical company, successfully completed the acquisition of Bionova Scientific, LLC, in an undisclosed transaction. This strategic acquisition enhances Asahi Kasei Medical's bioprocess business by integrating a biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The move broadens their customer base, particularly among those engaged in the development of cutting-edge next-generation biopharmaceuticals. Bionova Scientific LLC, a US-based company, specializes in offering contract process development services and Good Manufacturing Practice (GMP)-compliant contract manufacturing services for biopharmaceutical firms.

Major companies operating in the preclinical cro market report are Eurofins Scientific SE, PRA Health Sciences Inc., Wuxi AppTec Co. Ltd., Medpace Holdings Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, SGA SA, Intertek Group plc, Crown Bioscience International, Cynbiose, AmplifyBio LLC, Vivotecnia SL, Simavita Ltd., BioEmission Technology Solutions, Altasciences Company Inc., Global Center For Medical Innovation, Pharmaceutical Product Development LLC, Parexel International Corporation, Envigo RMS Holding Corporation, Veeda Clinical Research Ltd., ICON plc, Kunming Biomed International Ltd., PharmaLegacy Laboratories, NorthEast BioAnalytical Laboratories LLC, MDS Pharma Services, MPI Research, Toxikon Corporation, BioReliance Corporation, Covance Inc., Syngene International Limited.

North America was the largest region in the preclinical CRO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global preclinical CRO market during the forecast period. The regions covered in the preclinical cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preclinical cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The services offered by preclinical CROs cover a wide spectrum, including bioanalysis and DMPK studies, toxicology testing, compound management, chemistry, safety pharmacology, and more. A notable advancement in this domain is the adoption of patient-derived organoids (PDOs), which are small three-dimensional cell cultures created from a patient's cancer cells. Substantial investments and experimental validation efforts have been dedicated to PDOs, presenting promising therapeutic alternatives for diagnosing complex diseases. The repertoire of preclinical CRO services encompasses various models, such as the patient-derived organoid (PDO) model and patient-derived xenograft model, applicable to both small and large animal models. These model systems, spanning In Vivo and In Vitro approaches, find applications among biopharmaceutical companies, government and academic institutes, medical device companies, and other stakeholders.

The preclinical CRO market research report provides preclinical CRO market statistics, including preclinical CRO industry global market size, regional shares, competitors with an preclinical CRO market share, detailed preclinical CRO market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical CRO industry. This preclinical CRO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical CRO market includes revenues earned by entities through project management, information gathering, medical evaluations, maximum dose research, adherence to regulations, efficacy and safety reporting, and quality analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.